Preclinical models have shown that PARPi-based therapy synergizes with anti-programmed cell death protein 1 (PD-1) immunotherapy against both MSI-H and microsatellite stable (MSS) colon cancer models with a potential sensitizing effect of anti-PD-1 therapy against MSS tumours [115]. Here, PDCD1 is linked to colonic neoplasm.